Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 18/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 6/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11890052 | 0.79 | SLC6A2 (0.38) | ADRA1A | |
| SCHEMBL4100902 | 0.78 | ADRA1A (0.57) | ADRA1AADRA1DADRA1BKCNH2TACR1 | |
| SCHEMBL3665069 | 0.75 | HTR7 (0.39) | ADRA1A | |
| SCHEMBL11914169 | 0.75 | PROKR1 (0.33) | ADRA1A | |
| Hydrochloric Acid SCHEMBL4090775 | 0.74 | HTR7 (0.38) | ADRA1A | |
| SCHEMBL4088754 | 0.73 | ADRA1A (0.65) | ADRA1AADRA1DADRA1BKCNH2TACR1 | |
| SCHEMBL4093575 | 0.72 | ADRA1A (0.63) | ADRA1AADRA1DADRA1BKCNH2TACR1 | |
| SCHEMBL12188754 | 0.70 | HTR2C (0.50) | KCNH2 | |
| SCHEMBL4088745 | 0.70 | ADRA1A (0.57) | ADRA1AADRA1DADRA1BKCNH2TACR1 | |
| SCHEMBL13698242 | 0.69 | SLC6A2 (0.48) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288424-B2 | Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions | GRUENENTHAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186902-A1 | Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions | HRH4, TRPV1, QDPR | ADRA1A 517/4885ADRA1D 269/4885ADRA1B 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.